Значение альфа-адреноблокаторов при проведении лучевой терапии больным раком предстательной железы

Автор: Гриценко Сергей Ефимович, Кижаев Евгений Васильевич

Журнал: Вестник Российского научного центра рентгенорадиологии Минздрава России @vestnik-rncrr

Статья в выпуске: 2 т.17, 2017 года.

Бесплатный доступ

Представлены результаты анализа литературных данных по динамике изменений симптомов нижних мочевых путей (СНМП) пациентов, получивших различные виды лучевого лечения и альфа-адреноблокаторы в различные сроки. Всего было проанализировано 8 исследований, в которых применялись альфа1-адреноблокаторы для лечения СНМП у 1994 пациентов, получивших лучевую терапию по поводу рака предстательной железы. СНМП имеют место у пациентов, которым проводили дистанционную лучевую терапию или брахитерапию и являются результатом острого и хронического радиационного повреждения эпителиальных и стромальных элементов мочевого пузыря и уретры. Оценка СНМП проводилась с помощью шкалы оценки остроты лучевых повреждений RTOG, описания поздних лучевых повреждений по шкале SOMA- LENT, общих терминологических критериев неблагоприятных исходов CTCAE, а также шкалы IPSS. Данные исследований подтверждают, что СНМП после проведения лучевой терапии эффективно снижаются при приеме альфа-адреноблокаторов. Клинические исследования позволяют рекомендовать применение альфа-адреноблокаторов на самых ранних сроках возникновения СНМП, а также как метод профилактики СНМП, обусловленных эффектами лучевой терапии.

Еще

Альфа-адреноблокаторы, лучевая терапия, рак предстательной железы, снмп

Короткий адрес: https://sciup.org/14955545

IDR: 14955545

Список литературы Значение альфа-адреноблокаторов при проведении лучевой терапии больным раком предстательной железы

Каприн А., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2014 году (заболеваемость и смертность) МНИОИ им. П.А. Герцена филиал ФГБУ «ФМИЦ им. П.А. Герцена». 2016.
Abrams P., Schulman C.C., Vaage S. Tamsulosin, a selective _1c-adrenoceptor antagonist: a randomized, controlled trial in patients with benign prostatic ‘obstruction’ (symptomatic BPH). The European Tamsulosin Study Group. Br J Urol. 1995. V. 76. N. 3. P. 325-336.
Abrams P., Cardozo L., Fall M., et al. The Standardisation of Terminology of Lower Urinary Tract Function: Report from the Standardisaition Sub-committee of the International Continence Society. Neurourol Urodyn. 2002. V. 21. N. 2. P. 167-178.
Andersson K.E., Hedlund P. Pharmacologic perspective on the physiology of the lower urinary tract. Urology. 2002. V. 60. N. 5. Suppl. 1. P. 13-21.
Anscher M.S., Chen L., Rabbani Z,. et al. Recent progress in defining mechanisms and potential targets for prevention of normal tissue injury after radiation therapy. Int J Radiat Oncol Biol Phys. 2005. V. 62. N. 1. P. 255-259.
Akduman B., Crawford E.D. Terazosin, doxazosin, and prazosin: current clinical experience. Urology. 2001. V. 58. V.6. Suppl. 1. P. 49 -54.
Boyle P., Napalkov P. The epidemiology of benign prostatic hyperplasia and observations on concomitant hypertension. Scand J Urol Nephrol Suppl. 1995. V. 168. P. 7-12.
Brizel D.M., Wasserman T.H., Henke M., et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol. 2000. V. 18. N. 19. P. 3339 -3345.
Caine M., Pfau A., Perlberg S. The use of alpha-adrenergic blockers in benign prostatic obstruction. Br J Urol. 1976. V. 48. N. 4. P. 255-263.
Chapple C.R., Baert L., Thind P., et al. Tamsulosin 0.4 mg once daily: tolerability in older and younger patients with lower urinary tract symptoms suggestive of benign prostatic obstruction (symptomatic BPH). The European Tamsulosin Study Group. Eur Urol. 1997. V. 32. N. 4. P. 462-470.
Cooper K.L., McKiernan J.M., Kaplan S.A. Alpha-adrenoceptor antagonists in the treatment of benign prostatic hyperplasia. Drugs. 1999. V. 57. N. 1. P. 9-17.
Crawford E.D., Kavanagh B.D. The role of alpha-blockers in the management of lower urinary tract symptoms in prostate cancer patients treated with radiation therapy. Am J Clin Oncol. 2006. V. 29. N. 5. P. 517-523.
O’Donoghue J. Relevance of external beam dose-response relationships to kidney toxicity associated with radionuclide therapy. Cancer Biother Radiopharm. 2004. V. 19. N. 3. P. 378 -387.
Djavan B. Lower urinary tract symptoms/benign prostatic hyperplasia:fast control of the patient’s quality of life. Urology. 2003. V. 62. N. 3. Suppl. 1. P. 6 -14.
De Groat W.C. A neurologic basis for the overactive bladder. Urology. 1997. V. 50. N 6A Suppl. P. 36-52.
Elshaikh M.A., Ulchaker J.C., Reddy C.A., et al. Prophylactic tamsulosin (Flomax) in patients undergoing prostate 125I brachytherapy for prostate carcinoma: final report of a double-blind placebo-controlled randomized study. Int J Radiat Oncol Biol Phys. 2005. V. 62. N. 1. P. 164 -169.
Hampel C., Dolber P.C., Smith M.P., et al. Modulation of bladder alpha1-adrenergic receptor subtype expression by bladder outlet obstruction. J Urol. 2002. V. 167. N. 3. P. 1513-1521.
Harris M.I., Flegal K.M., Cowie C.C., et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care. 1998. V. 21. N. 4. P. 518 -524.
Hatano A., Takahashi H., Tamaki M,. et al. Pharmacological evidence of distinct alpha 1-adrenoceptor subtypes mediating the contraction of human prostatic urethra and peripheral artery. Br J Pharmacol. 1994. V. 113. N. 3. P. 723-728.
Henderson R.H., Hoppe B.S., Marcus R.B., et al. Urinary functional outcomes and toxicity five years after proton therapy for low-and intermediate-risk prostate cancer: results of two prospective trials. Acta Oncol. 2013. V. 52. N. 3. P. 463-469.
Janknegt R.A., Chapple C.R. Efficacy and safety of the alpha-1 blocker doxazosin in the treatment of benign prostatic hyperplasia. Analysis of 5 studies. Doxazosin Study Groups. Eur Urol. 1993. V. 24. N. 3. P. 319 -326.
Lepor H., Laddu A. Terazosin in the treatment of benign prostatic hyperplasia: the United States experience. Br J Urol. 1992. V. 70. Suppl. 1. P. 2-9.
Lepor H. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group. Urology. 1998. V. 51. N. 6.P. 892-900.
Linares L.A., Echols D. Amifostine and external beam radiation therapy and/or high-dose rate brachytherapy in the treatment of localized prostate carcinoma: preliminary results of a phase II trial. Semin Oncol. 2003. V. 30. N 6. Suppl. 18. P. 58-62.
Lopez-Beltran A., Luque R.J., Mazzucchelli R., et al. Changes produced in the urothelium by traditional and newer therapeutic procedures for bladder cancer. J Clin Pathol. 2002. V. 55. N. 9. P. 641-647.
Maartense S., Hermans J., Leer JW. Radiation therapy in localized prostate cancer: long-term results and late toxicity. Clin Oncol (R Coll Radiol). 2000. V. 12. N. 4. P. 222-228.
McDonald H., Hux M., Brisson M., et al. An economic evaluation of doxazosin, finasteride and combination therapy in the treatment of benign prostatic hyperplasia. Can J Urol. 2004. V. 11. N. 4. P. 2327-2340.
Menard C., Camphausen K., Muanza T., et al. Clinical trial of endorectal amifostine for radioprotection in patients with prostate cancer: rationale and early results. Semin Oncol. 2003. V. 30. N 6. Suppl. 18. P. 63-67.
Mornex F., Pavy J.J., Denekamp J., Bolla M. Scoring system of late effects of radiation on normal tissue: the SOMA-LENT scale. Cancer Radiother. 1997. V. 1. N. 6. P. 622-668.
Morris D.E., Emami B., Mauch P.M., et al. Evidence-based review of threedimensional conformal radiotherapy for localized prostate cancer: an ASTRO outcomes initiative. Int J Radiat Oncol Biol Phys. 2005. V. 62. N. 1. P. 3-19.
Merrick G.S., Butler W.M., Lief J.H., et al. Temporal resolution of urinary morbidity following prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2000. V. 47. N. 1. P. 121-128.
Merrick G.S., Butler W.M., Wallner K.E., et al. Prophylactic versus therapeutic alpha-blockers after permanent prostate brachytherapy. Urology. 2002. V. 60. N. 4. P. 650-655.
Narayan P., Tewari A. A Second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia. United States 93-01 Study Group. J Urol. 1998. V. 160. P. N. 5. P. 1701-1706.
Narayan P., Bruskewitz R. A Comparisonof two phase III multicenter, placebocontrolled studies of tamsulosin in BPH. Adv Ther. 2000. V. 17. N. 6. P. 287-300.
Narayan P., Evans C.P., Moon T. Long-term safety and effiacy of tamsulosin for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. J Urol. 2003. V. 170. N. 2. P. 498 -502.
Narayan P., O’Leary M., Davidai G. Early efficacy of tamsulosin vs terazosin in the treatment of men with benign prostatic hyperplasia: a randomized, open-label trial. J Appl Res. 2005. V. 5. N. 2. P. 237-245.
Okaneya T., Nishizawa S., Iijima K., et al. Clinical evaluation of lower urinary tract symptoms following seed implant for prostate cancer. 2012. V. 58. N. 4. P. 185-191.
Prosnitz R.G., Schneider L., Manola J., et al. Tamsulosin palliates radiation-induced urethritis in patients with prostate cancer: results of a pilot study. Int J Radiate Oncol Biol Phys. 1999. V. 45. N. 3. P. 563-566.
Russo P. Urologic emergencies in the cancer patient. Semin Oncol. 2000. V. 27. N. 3. P. 284-298.
Sarosdy M.F. Urinary and rectal complications of contemporary permanent transperineal brachytherapy for prostate carcinoma with or without external beam radiation therapy. Cancer. 2004. V. 101. N. 4. V. 754 -760.
Schwinn D.A., Michelott G.A. alpha 1-adrenergic receptors in the lower urinary tract and vascular bed: potential role for the alpha 1d subtype in filling symptoms and effects of ageing on vascular expression. BJU Int. 2000. V. 85. Suppl. 2. P. 6 -11.
Sugimura K., Carrington B.M., Quivey J.M., et al. Postirradiation changes in the pelvis: assessment with MR imaging. Radiology. 1990. V. 175. N. 3. P. 805-813.
Suresh U.R., Smith V.J., Lupton E.W., et al. Radiation disease of the urinary tract: histological features of 18 cases. J Clin Pathol. 1993. V. 46. N. 3. P. 228 -231.
Tsumura H., Satoh T., Ishiyama H., et al. Comparison of prophylactic naftopidil, tamsulosin, and silodosin for 125I brachytherapy-induced lower urinary tract symptoms in patients with prostate cancer: randomized controlled trial. Int J Radiat Oncol Biol Phys. 2011. V. 81. N. 4. P. 385-392.
Yablon C.M., Banner M.P., Ramchandani P., et al. Complications of prostate cancer treatment: spectrum of imaging findings. Radiographics. 2004. V. 24. Suppl 1. P. 181-194.
Zelefsky M.J., Wallner K.E., Ling C.C., et al. Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer. J Clin Oncol. 1999. V. 17. N. 2. P. 517-522.
Zelefsky M.J., Ginor R.X., Fuks Z., et al. Efficacy of selective alpha-1blocker therapy in the treatment of acute urinary symptoms during radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 1999. V. 45. N. 3. P. 567-570.
McVary K.T., Roehrborn C.G., Avins A.L., et al. Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol. 2011. V. 185. N. 5. P. 1793-1803.
Westfall T.C. Sympathomimetic Drugs and Adrenergic Receptor Antagonists Encyclopedia of nevroscience. 2009. Published by Elsevier Ltd V. P. 685-695. 008045046-9.01156-6 DOI: 10.1016/B978-
Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 U.S.DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Cancer Institute. 2009. (v4.03: June 14, 2010).
EAU Guidelines on European Association of Urology 2016 Management of Non-Neurogenic Male Lower UrinaryTract Symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO) S. Gravas (Chair), T. Bach, A. Bachmann, M. Drake, M. Gacci, C. Gratzke, S. Madersbacher, C. Mamoulakis, K.A.O. Tikkinen Guidelines Associates: M. Karavitakis, S. Malde, V. Sakkalis, R. Umbach http://uroweb.org/wp-content/uploads/EAU-Guidelines-Managementof-non-neurogenic-male-LUTS-2016.pdf.
RTOG/EORTC Late Radiation Morbidity Scoring Schema. https://www.rtog.org/researchassociates/adverseeventreporting/rtogeortclateradiationmorbidityscoringschema.aspx.
National Comprehensive Cancer Network Treatment Guidelines for Patients_ETO. Accessed. October 31, 2005.
RTOG/EORTC Radiation Toxicity Grading. Available at: https://en.wikibooks.org/wiki/Radiation_Oncology/Toxicity_grading/RTOG.

Еще

Статья научная